Enterococcus faecium bacteriophage wide-spectrum lyase and application thereof

By cloning and expressing the lysin from the phage IME199-lysin from the phage IME199, the drug resistance and phage safety of the phage are solved, and the efficient inhibition and killing of the phage is achieved, providing a safe and environmentally friendly treatment plan .

CN119020336AInactive Publication Date: 2024-11-26BEIJING UNIV OF CHEM TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310593059.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively isolate and purify the phage lyase of Enterococcus faecium, which leads to the resistant nature of the phage to antibiotics, and the safety and production of the phage are difficult, which affects its promotion and application.

Method used

The lysin lysin was cloned from the phage IME199 of E. faecium faecium, and the enzyme was induced to express through prokaryotic expression, and mass production was carried out in combination with recombinant vectors to ensure its stability and safety. It is used to inhibit and kill E. faecium faecium faecium. .

Benefits of technology

It has achieved efficient production and application of lyases with broad-spectrum antibacterial effects on Enterococcus faecium, with good temperature and pH stability, safe and environmentally friendly, and meets the needs of treatment and inhibition of Enterococcus faecium disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020336A_ABST
    Figure CN119020336A_ABST
Patent Text Reader

Abstract

The preparation method comprises the following steps: cloning from enterococcus faecium bacteriophage IME199 to obtain bacteriophage lyase IME199-lysin, and inducing to express dissolvable lyase by adopting a prokaryotic expression mode; the bacteriophage lyase IME199-lysin has a relatively strong bacteriostatic effect on enterococcus faecium, has a broad-spectrum bacteriostatic effect, and lays a foundation for treating and inhibiting enterococcus faecium diseases. The bacteriophage lyase IME199-lysin has better stability at the temperature of 4 to 65 DEG C and the pH value of 4 to 11. Besides, the bacteriophage lyase IME199-lysin has the advantages of being safe to use and environmentally friendly, large-batch production is carried out through a recombinant expression vector, and the production requirements of popularization and application can be met.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of bioengineering, and in particular to an Enterococcus faecium phage broad-spectrum lytic enzyme and application thereof. Background Art

[0002] Enterococci are facultative anaerobic Gram-positive bacteria that are intestinal commensals in humans. Enterococci are well-known opportunistic pathogens that can cause many infectious diseases, including bacteremia, urinary tract infections (UTIs), endocarditis, and intra-abdominal or intra-pelvic infections.

[0003] Current treatment for E. faecium relies primarily on antibiotics. However, because E. faecium is intrinsically resistant to a range of antibiotics, including aminoglycosides, β-lactams, cephalosporins, and sulfonamides, this property enables E. faecium to develop antibiotic resistance in healthcare settings where antibiotic treatment is common. Due to its multidrug resistance, the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have designated vancomycin-resistant E. faecium (VRE-fm) as a priority for the development of new drugs.

[0004] Bacteriophages are a type of virus that can specifically identify and infect bacteria. They are widely present in nature, and no matter how serious the pathogenic bacteria are, they can find their corresponding phages in nature. Compared with traditional antibiotic treatments, phages have unique advantages: they do not produce widespread drug resistance; phages use hosts to reproduce, and a small single dose can kill bacteria; they do not destroy the ecology of the bacterial flora in the body. However, phages are living viruses after all, and their genomes may contain integrase genes, so their absolute safety cannot be guaranteed in actual use. This is also a major problem that seriously affects the promotion and application of phage preparations.

[0005] Lytic enzymes derived from bacteriophages are essentially a type of protease that can lyse and destroy bacterial cell walls, thereby having the ability to kill bacteria. As a new type of antibacterial agent with higher safety, phage lytic enzymes have a wider application advantage than antibiotics and bacteriophages. However, effective phage lytic enzymes from Enterococcus faecium have not yet been isolated, purified or developed, and used to inhibit and kill Enterococcus faecium. How to solve the above technical problems is a technical problem that needs to be solved in the field of bioengineering technology. Summary of the invention

[0006] In order to solve the above problems existing in the prior art, the present invention aims to provide an Enterococcus faecium phage lytic enzyme and a preparation method and application thereof.

[0007] The technical solution adopted by the present invention is:

[0008] The present invention provides an Enterococcus faecium phage lytic enzyme IME199-lysin, wherein the Enterococcus faecium phage lytic enzyme is selected from the following group:

[0009] (a) a protein consisting of the amino acid sequence shown in SEQ NO: 2;

[0010] (b) a protein having at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identity with the amino acid sequence shown in SEQ NO: 2 and having the function of lysing Enterococcus faecium.

[0011] The present invention also provides a composition, which comprises the above-mentioned Enterococcus faecium phage lytic enzyme IME199-lysin and a pharmaceutically acceptable carrier, diluent or excipient.

[0012] The present invention also provides a nucleic acid molecule encoding the Enterococcus faecium phage lytic enzyme IME199-lysin.

[0013] In some embodiments, the nucleic acid molecule may be DNA, such as cDNA, genomic DNA or recombinant DNA; the nucleic acid molecule may also be RNA, such as mRNA, hnRNA or tRNA.

[0014] In some embodiments, the nucleic acid molecule is selected from the group consisting of:

[0015] 1) The coding sequence is a DNA molecule shown in SEQ NO: 1;

[0016] 2) the DNA molecule shown in SEQ NO: 1;

[0017] 3) a DNA molecule that hybridizes with the DNA molecule defined in 1) or 2) under stringent conditions and encodes the Enterococcus faecium bacteriophage lytic enzyme IME199-lysin;

[0018] 4) A DNA molecule having more than 90% homology with the DNA molecule defined in 1) or 2) or 3) and encoding the Enterococcus faecium phage lytic enzyme IME199-lysin.

[0019] The above stringent conditions may be hybridization with a solution of 6×SSC, 0.5% SDS at 65°C, followed by washing the membrane once with 2×SSC, 0.1% SDS and once with 1×SSC, 0.1% SDS.

[0020] The present invention also provides a recombinant vector, an expression cassette, a host cell or a recombinant bacterium comprising the above nucleic acid molecule.

[0021] In some embodiments, the recombinant vector may be a recombinant expression vector or a recombinant cloning vector.

[0022] The present invention also provides the use of the Enterococcus faecium phage lytic enzyme IME199-lysin, nucleic acid molecules, recombinant vectors, expression cassettes, host cells or recombinant bacteria in preparing products for killing and / or lysing Enterococcus faecium in vivo or in vitro.

[0023] The present invention also provides the use of the above-mentioned Enterococcus faecium phage lytic enzyme IME199-lysin, nucleic acid molecule, recombinant vector, expression cassette, host cell or recombinant bacteria in preparing products for treating diseases caused by Enterococcus faecium infection.

[0024] The present invention also provides a method for preparing the above-mentioned Enterococcus faecium phage lytic enzyme IME199-lysin, and the preparation method comprises the following steps:

[0025] The gene shown in SEQ NO: 1 was cloned and expressed, and then connected to a vector, and then the expression plasmid was transferred into Escherichia coli for expression.

[0026] In some embodiments, the preparation method comprises the following steps: cloning and expressing the gene shown in SEQ NO: 1, and then connecting it to the pET28a vector, and then transferring the expression plasmid into Escherichia coli BL21 (DE3) for expression.

[0027] In some embodiments, the preparation method optionally further comprises purifying the expressed lytic enzyme via a nickel column.

[0028] Compared with the prior art, the advantages and beneficial effects of the present invention are as follows:

[0029] The present invention clones the phage lytic enzyme IME199-lysin from the Enterococcus faecium phage IME199, and adopts a prokaryotic expression method to induce the expression of a soluble lytic enzyme; the phage lytic enzyme IME199-lysin has a strong antibacterial effect on Enterococcus faecium, and has a broad-spectrum antibacterial effect, laying a foundation for the treatment and inhibition of Enterococcus faecium diseases. The phage lytic enzyme IME199-lysin has good stability at a temperature of 4-65°C and a pH of 4-11. In addition, the phage lytic enzyme IME199-lysin has the advantages of safe use and environmental protection, and can be mass-produced through a recombinant expression vector to meet the production needs of promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The results of PCR amplification of IME199-lysin gene. In the figure, M is DNA Marker; 199 is the PCR amplification band of IME199-lysin gene, with a size of 915 bp.

[0031] Figure 2The PCR amplification results of a single colony after the IME199-lysin gene was connected to the vector. In the figure, M is a DNA marker; C is the PCR amplification result of the pET28a empty vector; 1-5 are the expansion results of the IME199-lysin gene of a single colony lytic enzyme, and the size of the IME199-lysin gene is 915bp.

[0032] Figure 3 The SDS-PAGE results of prokaryotic cells expressing lytic enzymes. In the figure, M is a protein marker; A is the whole bacterial solution before IPTG induction; B is the supernatant after disruption; C and D are the purified lytic enzymes IME199-lysin. The size of the lytic enzyme IME199-lysin (including the His tag) is 37.6 kDa and is located in the red box.

[0033] Figure 4 This study investigates the in vitro antibacterial activity of IME199-lysin against Enterococcus faecium 4050.

[0034] Figure 5 This is a plate diagram showing the antibacterial effect of bacteriophage IME199 and lytic enzyme IME199-lysin on Enterococcus faecium 4050.

[0035] Figure 6 The temperature stability results of the lysing enzyme IME199-lysin are shown in FIG.

[0036] Figure 7 The pH stability results of IME199-lysin. DETAILED DESCRIPTION

[0037] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0038] Example 1: Cloning and vector construction of Enterococcus faecium phage lytic enzyme IME199-lysin

[0039] 1.1 Strains and vectors

[0040] Escherichia coli DH5α competent cells and Escherichia coli BL21 competent cells were purchased from Beijing Solebow Technology Co., Ltd. The expression vector pET28a and Enterococcus faecium phage IME199 were deposited in the laboratory.

[0041] 1.2 Primer design

[0042] According to the complete genome sequence of bacteriophage SA2, the lytic enzyme IME199-lysin gene sequence of bacteriophage IME199 was determined. According to the target gene sequence and the sequence of the expression vector pET28a, the primers were designed using the online website provided by Vazyme, and HindⅢ and BamHI restriction sites were added to both ends of the primers. The primers were synthesized by Beijing Ruiboxing Biotechnology Co., Ltd.

[0043] IME199-lysin F:ctcgagtgcggccgcaagcttATGATTACAAAAGGAATTGCTGGA

[0044] IME199-lysin R:cagcaaatgggtcgcggatccTTATAGTGTTAAATAGATAGAATCGATACGAA

[0045] 1.3 PCR amplification and recovery

[0046] 1 μL of gene was used as template and 1 μL of upstream and downstream primers were used for PCR amplification. The PCR amplification program conditions were as follows: 94℃ pre-denaturation for 5 min; 94℃ denaturation for 30 sec, 61℃ annealing for 30 sec, 72℃ extension for 90 sec, 35 cycles; and finally 72℃ extension for 5 min. The PCR amplification product was checked by 1% agarose gel electrophoresis, and the target band consistent with the expected size of 915 bp was obtained. Figure 1 . Use the full-form gold DNA gel recovery kit to recover the target fragment amplified by PCR.

[0047] 1.4 Ligation of recombinant expression plasmid and transformation of competent cells

[0048] The expression vector pET28a plasmid was subjected to double enzyme digestion reaction, and the enzyme digestion system was verified by 1% agarose gel electrophoresis, and the gel was recovered to obtain a vector with sticky ends. The lysase IME199-lysin gene was connected to the expression plasmid pET28a. 10μL of the ligation product was added to 100μL of Escherichia coli DH5α competent cells, gently mixed, and ice bathed for 30min. Heat shock in a 42℃ water bath for 90s, and quickly placed on ice for 2-3min. Add 890μL of fresh LB medium and culture at 37℃ for 60min. Centrifuge at 12,000×g for 5min, discard 800μL of supernatant and resuspend the bacterial solution. Take 100μL of bacterial solution and spread it on the nutrient agar plate containing Amp. After the liquid is completely absorbed, invert and culture it at 37℃ overnight.

[0049] 1.5 Sequencing of recombinant expression plasmid to identify target gene

[0050] Randomly pick 10 single clones on the Kan plate, pipette them into 10 μL PBS, take 1 μL to identify positive clones by PCR, and check the enzyme digestion products by 1% agarose gel electrophoresis. Figure 2 The positive clones were then inoculated into fresh LB medium to obtain bacterial suspension. The positive bacterial suspension was sequenced and the target gene was aligned using SnapGene software. The results showed that the gene inserted into the recombinant plasmid was consistent with the target gene sequence.

[0051] Example 2 Induced expression and purification of recombinant expression plasmid bacteria

[0052] 2.1 Transformation of recombinant expression plasmid into BL21 competent cells

[0053] Take 10 μL of recombinant plasmid and add 100 μL of Escherichia coli BL21 competent cells, mix well and place on ice for 30 minutes; heat shock in a 42°C water bath for 90 seconds, quickly place on ice for 3 minutes, add 1 mL of LB broth, and culture at a constant temperature of 37°C for 90 minutes; take 100 μL of bacterial solution and spread it on a nutrient agar plate containing Kan, and culture it at a constant temperature of 37°C overnight.

[0054] 2.2 Induced expression and purification of recombinant expression plasmid

[0055] Randomly pick a single colony transferred into BL21 competent cells, inoculate it into LB liquid medium containing Kan, shake and culture at 37℃ until OD600 is about 0.6-0.8, add IPTG with a final concentration of 0.1mM, and shake at 16℃ overnight to induce expression. Resuspend the bacteria in TrisBuffer and break the cells using a low-temperature high-pressure cell disruptor. After the bacteria are lysed, centrifuge at 4℃, take the supernatant and further purify it through a nickel column to obtain the lytic enzyme IME199-lysin. Take the bacteria before induction, the supernatant after disruption, and the protein after nickel column purification for SDS-PAGE electrophoresis analysis, see Figure 3 The results showed that the IME199-lysin recombinant protein was expressed in a soluble form.

[0056] Example 3 Determination of in vitro antibacterial activity and antibacterial spectrum of lysase IME199-lysin

[0057] 3.1 Determination of in vitro antibacterial activity of IME199-lysin

[0058] Enterococcus faecium was cultured in LB liquid medium to the logarithmic phase. After centrifugation, the precipitate was washed twice with PBS and then resuspended in PBS. An equal volume of the resuspended bacterial solution was mixed with IME199-lysin (final concentration was 250 μg / mL), incubated at 37°C for 1 hour, and the bactericidal effect was calculated by the dilution plate counting method. In vitro bactericidal activity is shown in Figure 4 , the sterilization amount can reach 1 order of magnitude within 45 minutes of reaction.

[0059] 3.2 Detection of antibacterial spectrum of IME199-lysin

[0060] In order to further verify the antibacterial spectrum of the Enterococcus faecium phage lytic enzyme IME199-lysin, 77 strains of Enterococcus faecium preserved in the laboratory were selected as test bacteria to study the antibacterial spectrum of the lytic enzyme. The strains to be tested were cultured at 37°C overnight and entered the logarithmic growth phase. By the double-layer plate method, 5 μL of lytic enzyme IME199-lysin and phage IME199 were spotted on the plates containing bacteria. The lytic enzyme IME199-lysin was divided into high concentration (2.1 mg / mL) and low concentration (0.3 mg / mL); the titer of phage IME199>10 8 PFU / mL. Cultured in a 37℃ incubator.

[0061] The results showed that the lytic enzyme IME199-lysin had a significant antibacterial effect on 77 strains of Enterococcus faecium from different sources at high concentrations, with a lysis rate of 100%; the lytic enzyme IME199-lysin had a significant antibacterial effect on 39 strains of Enterococcus faecium from different sources at low concentrations, with a lysis rate of 51%; the phage IME199 had an antibacterial effect on only 6 strains of Enterococcus faecium from different sources, with a lysis rate of 8%. It can be seen that the antibacterial spectrum of the lytic enzyme IME199-lysin is significantly wider than that of the Enterococcus faecium phage IME199. Figure 5 The specific results of the antibacterial spectrum are shown in Table 1.

[0062] Table 1 Antibacterial spectrum detection experimental results

[0063]

[0064]

[0065] Example 4 Determination of temperature stability and pH stability of lyase IME199-lysin 4.1 Determination of temperature stability of lyase IME199-lysin

[0066] Enterococcus faecium was cultured to the logarithmic phase, the cells were collected by centrifugation, washed three times with PBS, resuspended and diluted to 2×10 7 CFU / mL, evenly divided into 2mL centrifuge tubes. 500μg / mL IME199-lysin protein was first incubated at different temperatures for 30min. After the incubation, it was mixed with an equal volume of bacterial solution, cultured at 37℃ for 1h, and counted by dilution coating plates. The value of the reduction in bacterial count in each group compared with the blank group was calculated, and the value with the largest reduction in bacterial count was defined as 100%. The reduction values ​​of bacterial counts in other groups were compared with it to obtain the relative enzyme activity value. The temperature relative activity of IME199-lysin is shown in Figure 6 The results showed that IME199-lysin had strong temperature stability and exhibited good cleavage activity at 4-65°C, and its cleavage activity was strongest when the temperature was around 37°C.

[0067] 4.2 Determination of pH stability of IME199-lysin

[0068] Bacteria were collected according to the above method, resuspended in PBS buffer with different pH (4-11), and equal amounts of purified IME199-lysin (500 μg / mL) were added. After incubation at 37°C for 1 hour, the diluted plates were counted. The value of the reduction in the number of bacteria in each group compared with the blank group was calculated, and the value with the largest reduction in the number of bacteria was defined as 100%. The reduction values ​​of the number of bacteria in other groups were compared with it to obtain the relative enzyme activity value. The temperature relative activity of IME199-lysin is shown in Figure 7 The results showed that IME199-lysin adapted to a wide pH range, with higher lytic activity at pH 6-9, and still maintained a certain lytic activity under pH 4 and pH 11.

[0069] Sequence information

[0070] SEQ ID NO: 1 (IME199-lysin gene sequence):

[0071] atgattacaaaaggaattgctggacgtagacaaggaaaagtaaaaggtgttgtgattcataatgatgctggttcaaatggagcaacttgctcttttta

[0072] tagagggtatttaactgatgcgaatgccgcctatggttttgcacattggtatgtcgcttcggacggtattttacaagtggaagatgaatcaaatatgg

[0073] catggcatacagcaaatagctatgggaatgccaattttattgggattgaagcttgtcagtcgatggggaacttagctcaatttttagaaaatgagaa

[0074] acgggcgattaaattagcagctgaaattttaaaacgtcatggtttaaccccaaatacaacgactgtacgattgcacaatacttttagctcaaccgctt

[0075] gtcctcaccgctcacaagagcagcatggggctggtagtaaaacacaagcttattttattgctgaaataaaaaaacacatgaatgggtcaactccc

[0076] gctccttctaaaccaacaacgccaagtcaacatgataaagcagtatctgcaagtccagcaaaacatcaaggcaatgcatggggtaaacttgataa

[0077] gtatcgtgaagagcctgctgggaaaattcgtgtggctggttggttagttcctgataaaccacaaggcccaattggaaaatatgcgtacgtcatcttt

[0078] atgcaacatggaacaaacaaagagttgacacgtgttcaatctgctggcattaaacgcccagacgtgaagaaagcatacagctatcaaggtggg

[0079] caagagcttgggtttgatgtaactgttaagaaagctcagttcaaaggtaaaaaagtagatgttatcttgcgtagagcgaataaagctaatggtgaa

[0080] gtcgcagtaaatgatgttcgtatcgattctatctatttaacactataa

[0081] SEQ ID NO:2 (Amino acid sequence of IME199-lysine):

[0082] MITKGIAGRRQGKVKGVVIHNDAGSNGATCSFYRGYLTDANAAYGFAHWYVASDGILQV

[0083] EDESNMAWHTANSYGNANFIGIEACQSMGNLAQFLENEKRAIKLAAEILKRHGLTPNTTTV

[0084] RLHNTFSSTACPHRSQEQHGAGSKTQAYFIAEIKKHMNGSTPAPSKPTTPSQHDKAVSASP

[0085] AKHQGNAWGKLDKYREEPAGKIRVAGWLVPDKPQGPIGKYAYVIFMQHGTNKELTRVQS

[0086] AGIKRPDVKKAYSYQGGQELGFDVTVKKAQFKGKKVDVILRRANKANGEVAVNDVRIDSI

[0087] YLTL

Claims

1. An Enterococcus faecium phage lytic enzyme IME199-lysin, wherein the Enterococcus faecium phage lytic enzyme is selected from the following group: (a) a protein consisting of the amino acid sequence shown in SEQ NO: 2; (b) a protein having at least 80% (preferably at least 85%, more preferably at least 90%, further preferably at least 95%, for example 99%) identity with the amino acid sequence shown in SEQ NO: 2 and having the function of lysing Enterococcus faecium.

2. A composition comprising the Enterococcus faecium phage lytic enzyme IME199-lysin according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

3. A nucleic acid molecule encoding the Enterococcus faecium phage lytic enzyme IME199-lysin according to claim 1.

4. The nucleic acid molecule according to claim 3, characterized in that The nucleic acid molecule is selected from the group consisting of: 1) The coding sequence is a DNA molecule shown in SEQ NO: 1; 2) the DNA molecule shown in SEQ NO: 1; 3) a DNA molecule that hybridizes with the DNA molecule defined in 1) or 2) under stringent conditions and encodes the Enterococcus faecium bacteriophage lytic enzyme IME199-lysin; 4) A DNA molecule having 90% or more homology with the DNA molecule defined in 1) or 2) or 3) and encoding the Enterococcus faecium phage lytic enzyme IME199-lysin.

5. A recombinant vector, expression cassette, host cell or recombinant bacterium comprising the nucleic acid molecule according to claim 3 or 4.

6. Use of the Enterococcus faecium bacteriophage lytic enzyme IME199-lysin according to claim 1, the nucleic acid molecule according to claim 3 or 4, and the recombinant vector, expression cassette, host cell or recombinant bacteria according to claim 5 in the preparation of a product for killing and / or lysing Enterococcus faecium in vivo or in vitro.

7. Use of the Enterococcus faecium phage lytic enzyme IME199-lysin according to claim 1, the nucleic acid molecule according to claim 3 or 4, and the recombinant vector, expression cassette, host cell or recombinant bacteria according to claim 5 in the preparation of a product for treating a disease caused by Enterococcus faecium infection.

8. The method for preparing the Enterococcus faecium phage lytic enzyme IME199-lysin according to claim 1, comprising the following steps: The gene shown in SEQ NO: 1 was cloned and expressed, and then connected to a vector, and then the expression plasmid was transferred into Escherichia coli for expression; Preferably, the preparation method further comprises purifying the expressed lyase via a nickel column.

Citation Information

Patent Citations

  • Enterococcus faecalis phage lyase and coding gene and application thereof

    CN103667230A

  • Enterococcal phage peptides and methods of use thereof

    WO2011065854A1